Article info

Download PDFPDF
Randomised Controlled Trial
Low-dose rosiglitazone plus metformin reduces risk of incident type 2 diabetes compared with placebo in people with impaired glucose tolerance
  1. Correspondence to Professor Philip Home
    ICM-Diabetes, The Medical School, Framlington Place, Newcastle upon Tyne NE2 4HH, UK; philip.home{at}ncl.ac.uk
View Full Text

Citation

Home PD
Low-dose rosiglitazone plus metformin reduces risk of incident type 2 diabetes compared with placebo in people with impaired glucose tolerance

Publication history

  • First published November 16, 2010.
Online issue publication 
January 20, 2011

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.